Funding news
Tavo Biotherapeutics logo

Tavo Biotherapeutics Raises $1

Recently funded · $17.0M Series aHospitals and Health CareView source

Get the full Tavo Biotherapeutics company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Tavo Biotherapeutics, a biotech firm focused on ophthalmology, has closed a $17.0M Series A funding round. The capital infusion will advance its pipeline of innovative treatments for critical unmet needs in eye care.

The company is developing TAV-001, a potential disease-modifying therapy for glaucoma-related neurodegeneration, which is slated to enter Phase 1 clinical trials in 2025. Its second program, TAV-002, targets retinal diseases like diabetic retinopathy and age-related macular degeneration, with IND-enabling activities already underway.

From the source

FinSMEs · Jun 2, 2026

Tavo Biotherapeutics, a Laguna Beach, California-based developer of novel therapies for glaucoma and retinal disease, raised $17m in Series A funding https://lnkd.in/duqypjSp / Access the FinSMEs Intelligence Hub using the code DISCOUNTFOUNDER for 30% off! 👉 https://lnkd.in/dCSjx_V3

Other recently funded companies

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
Alitheon logo

Alitheon

United States

$8.0M
2
Adaptive Innovations Corp logo

Adaptive Innovations Corp

United States

$50.0M
3
Novellia logo

Novellia

United States

$18.0M
4
GenerativeX logo

GenerativeX

United States

$650.0M
5
Sekai logo

Sekai

United States

$20.0M